The 36-month beta value for CRBP is at 2.53. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRBP is 10.38M, and currently, shorts hold a 6.00% of that float. The average trading volume for CRBP on May 09, 2024 was 281.87K shares.
CRBP) stock’s latest price update
Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has seen a rise in its stock price by 2.13 in relation to its previous close of 42.39. However, the company has experienced a 13.34% gain in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-19 that Small-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again.
CRBP’s Market Performance
Corbus Pharmaceuticals Holdings Inc (CRBP) has experienced a 13.34% rise in stock performance for the past week, with a 13.49% rise in the past month, and a 100.16% rise in the past quarter. The volatility ratio for the week is 6.83%, and the volatility levels for the past 30 days are at 8.01% for CRBP. The simple moving average for the past 20 days is 13.30% for CRBP’s stock, with a 167.45% simple moving average for the past 200 days.
Analysts’ Opinion of CRBP
Many brokerage firms have already submitted their reports for CRBP stocks, with Jefferies repeating the rating for CRBP by listing it as a “Buy.” The predicted price for CRBP in the upcoming period, according to Jefferies is $46 based on the research report published on March 06, 2024 of the current year 2024.
ROTH Capital, on the other hand, stated in their research note that they expect to see CRBP reach a price target of $3, previously predicting the price at $40. The rating they have provided for CRBP stocks is “Neutral” according to the report published on September 08th, 2020.
CRBP Trading at 12.83% from the 50-Day Moving Average
After a stumble in the market that brought CRBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.18% of loss for the given period.
Volatility was left at 8.01%, however, over the last 30 days, the volatility rate increased by 6.83%, as shares surge +9.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +56.29% upper at present.
During the last 5 trading sessions, CRBP rose by +14.55%, which changed the moving average for the period of 200-days by +567.07% in comparison to the 20-day moving average, which settled at $38.40. In addition, Corbus Pharmaceuticals Holdings Inc saw 616.80% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRBP starting from Cormorant Asset Management, LP, who purchase 300,000 shares at the price of $44.38 back on Mar 08 ’24. After this action, Cormorant Asset Management, LP now owns 2,025,000 shares of Corbus Pharmaceuticals Holdings Inc, valued at $13,314,193 using the latest closing price.
Cormorant Asset Management, LP, the 10% Owner of Corbus Pharmaceuticals Holdings Inc, purchase 250,000 shares at $40.05 during a trade that took place back on Mar 07 ’24, which means that Cormorant Asset Management, LP is holding 1,725,000 shares at $10,013,367 based on the most recent closing price.
Stock Fundamentals for CRBP
Current profitability levels for the company are sitting at:
- -25.69 for the present operating margin
- 0.66 for the gross margin
The net margin for Corbus Pharmaceuticals Holdings Inc stands at -25.01. The total capital return value is set at -0.35. Equity return is now at value -59.52, with -38.06 for asset returns.
Based on Corbus Pharmaceuticals Holdings Inc (CRBP), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -1.67. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -66.98.
Currently, EBITDA for the company is -44.44 million with net debt to EBITDA at -0.09. When we switch over and look at the enterprise to sales, we see a ratio of 338.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.69.
Conclusion
In conclusion, Corbus Pharmaceuticals Holdings Inc (CRBP) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
